BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • Contact Us
Archives
  • May 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • September 2024
  • August 2024
  • July 2024
  • May 2024
  • April 2024
  • December 2023
  • October 2023
  • August 2023
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • December 2021
  • November 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • Contact Us
Subscribe

Browsing Tag

Multikine

8 posts

Biotech NewsPathology and Oncology Research Publishes Landmark Phase 3 Study: Multikine Immunotherapy Significantly Improves Survival and Quality of Life in Head and Neck Cancer Patients

  • BioTech Health X
  • March 24, 2025
Recent advancements in cancer immunotherapy have brought promising news for patients battling head and neck squamous cell carcinoma…
0 Shares
0
0
0
0
0
0
0

BioTech CEO InterviewsGeert Kersten on CEL-SCI’s Multikine and the Future of Immunotherapy – Exclusive Interview

  • BioTech Health X
  • May 25, 2024
In this exclusive interview, host Allison Godlove sits down with CEL-SCI (NYSEAMERICAN: CVM) CEO Geert Kersten to delve…
0 Shares
0
0
0
0
0
0
0

Biotech NewsCEL-SCI Advances in Cancer Treatment with FDA Approval for Confirmatory Multikine Study

  • BioTech Health X
  • May 8, 2024
In a landmark decision, the U.S. Food and Drug Administration (FDA) has green-lighted CEL-SCI Corporation (NYSE American: CVM)…
0 Shares
0
0
0
0
0
0
0
CEL-SCI Multikine Phase 3 Data Highlighted at ESMO 2022

Biotech NewsCEL-SCI Multikine Phase 3 Data Highlighted at ESMO 2022

  • BioTech Health X
  • September 10, 2022
CEL-SCI recently presented its Phase 3 data at ESMO 2022, which revealed that Neoadjuvant Multikine achieved groundbreaking tumor…
0 Shares
0
0
0
0
0
0
0
Merck Announces Failure in Keytruda Head and Neck Cancer Phase 3 Clinical Trial

Biotech NewsMerck Announces Failure in Keytruda Head and Neck Cancer Phase 3 Clinical Trial

  • BioTech Health X
  • July 20, 2022
Today Merck & Co. (NYSE: MRK) announced that Keytruda has failed the Phase 3 clinical trial KEYNOTE-412 evaluating…
0 Shares
0
0
0
0
0
0
0
EF Hutton Initiates Coverage of Cel-Sci CVM with 17 Price Target Ahead of Rumored News

Biotech NewsEF Hutton Initiates Coverage of Cel-Sci (CVM) with $17 Price Target Ahead of Rumored News

  • BioTech Health X
  • April 7, 2022
Tim Moore, CFA an Analyst at EF Hutton has recently published a report citing the opportunities for growth…
0 Shares
0
0
0
0
0
0
0
Exclusive Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future

BioTech CEO InterviewsExclusive: Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future

  • BioTech Health X
  • September 3, 2021
About Cel-Sci Corporation Cel-Sci Corporation is a publicly traded biotechnology business which develops, manufactures, and markets treatments focused…
0 Shares
0
0
0
0
0
0
0
Cel-Sci Announces Multikine Immunotherapy Significantly Improves Overall Survival Benefit for Cancer Head Neck Patients in Phase 3 Trial

Biotech NewsCel-Sci Announces Multikine Immunotherapy Significantly Improves Overall Survival Benefit for Cancer Head & Neck Patients in Phase 3 Trial

  • BioTech Health X
  • June 28, 2021
Data Shows Significant Overall Survival Benefit for Cancer Patients with Multikine Treatment Regimen Followed by Surgery & Radiotherapy…
0 Shares
0
0
0
0
0
0
0
Recent Posts
  • Denali Therapeutics: The Future of Neuroscience Innovation
  • Spok Holdings: A Top Healthcare Communication Stock to Watch in 2025
  • Allogene Therapeutics (ALLO): The Future of Off-the-Shelf CAR T Cancer Therapy
  • Investors Are Watching XOMA Ahead of 2025’s Major Clinical Readouts
  • Pathology and Oncology Research Publishes Landmark Phase 3 Study: Multikine Immunotherapy Significantly Improves Survival and Quality of Life in Head and Neck Cancer Patients
Recent Comments
  • Novavax Announces Robust First Quarter 2024 Results and Strategic Partnerships • BioTech Health X on Novavax and Sanofi Forge $1.2 Billion Alliance to Boost COVID and Flu Vaccine Efforts
  • Thomas Shentz on Cellarity Expands Leadership Team to Continue Evolution of Breakthrough Platform to Encode Biology and Purposefully Create New Drugs
  • Tomasz Michałowski on Exclusive: Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future
  • Presenters Announced for 2021 William Blair Biotech Conference • BioTech Health X on William Blair Biotech Focus Conference 2021 Panel Schedule
Featured Posts
    • May 10, 2025
    Denali Therapeutics: The Future of Neuroscience Innovation
    • May 10, 2025
    Spok Holdings: A Top Healthcare Communication Stock to Watch in 2025
    • May 10, 2025
    Allogene Therapeutics (ALLO): The Future of Off-the-Shelf CAR T Cancer Therapy
    • May 10, 2025
    Investors Are Watching XOMA Ahead of 2025’s Major Clinical Readouts
    • March 24, 2025
    Pathology and Oncology Research Publishes Landmark Phase 3 Study: Multikine Immunotherapy Significantly Improves Survival and Quality of Life in Head and Neck Cancer Patients
Recent Posts
  • Aptose Biosciences (APTO) Stock Soars 31.50%: A Penny Stock on the Rise
    • February 23, 2025
  • CEL-SCI Corporation: Leading the Future of Cancer Immunotherapy with Multikine®
    • February 20, 2025
  • Ginkgo Bioworks (DNA): A Leader in Synthetic Biology Driving Innovation in 2024
    • February 8, 2025
Categories
  • BioTech CEO Interviews (9)
  • Biotech Info (1)
  • Biotech News (132)
  • Uncategorized (1)
Author
Hello, I’m
BioTech Health X
Follow
BioTech Health X
Designed & Developed by BioTech Health X
  • About BioTech Health X
  • List of Modern Life Science Technologies
  • Biotechnology Company Directory – List of Major Biotech Companies
  • Contact Us
  • Privacy Policy

Subscribe to
Our Updates

Back to top